Citations

Clear

16280 citation(s) found for "Yu, David".

Deriving severity thresholds of treatment burden for the patient experience with treatment and self-management (PETS)
Eton, David T. , Yost, Kathleen J.

Mayo Clinic

Journal of Multimorbidity and Comorbidity | June 23, 2025 | Volume: 15 | Issue: No issue available | Pages: No page available

10.1177/26335565251350923 | PMID 40557033 Get It

Objective The Patient Experience with Treatment and Self-management (PETS) is a valid self-report measure of treatment burden. The objective of this analysis is to determine severity cut points for its scores. Methods Data from two survey studies of adults with multimorbidity were used to determine estimates of low, moderate, and high burden for twelve PETS scores. Anchor-based analyses were used to map mean PETS scores onto scores of other self-report measures, including physical and mental health, self-efficacy, and activity limitations. Low, medium, and high scores on the anchors were based on published thresholds or tertile splits of score distributions. Mean PETS scores were compared across levels of the anchor variable using analysis of variance (ANOVA) then summarized to produce burden severity cut points. Results Study 1 featured survey data from 332 adults with multimorbidity (mean age = 66 years, 56% female); study 2 featured survey data from 439 adults with multimorbidity (mean age = 60 years, 62% female). Anchor measures were correlated with PETS scores at rho≥ 0.30. ANOVAs comparing PETS scores across the levels of each anchor variable were all significant ( p s< .001). Estimates were placed into data tables. Cut scores for discriminating treatment burden severity levels were identified as the midpoint between the mean PETS scores associated with adjacent anchor categories (e.g., low vs. medium and medium vs. high burden), rounded to the nearest whole number. Conclusions Severity thresholds can improve the interpretability of PETS scores. The preliminary estimates derived require verification in future studies.
Inadequately Controlled Type 2 Diabetes and Hypercortisolism: Improved Glycemia With Mifepristone Treatment
DeFronzo, Ralph A. , Fonseca, Vivian , Aroda, Vanita R. , Auchus, Richard J. , Busch, Robert S. , Buse, John B. , Christofides, Elena A. , Eilerman, Bradley , Findling, James W. , Handelsman, Yehuda , Miller, Harold J., Ownby, Jonathan G., Parker, John C. , Philis‐Tsimikas, Athena , Rosenstock, Julio , Shanik, Michael H., Sloan, Lance Alan , Shambharkar, Samir, Tudor, Iulia Cristina , Schlafly, Tina K. , Einhorn, Daniel , Investigators*, CATALYST, Kruszon, Lauren, Fruiterman, Abbey, Heidarpour, Narges, Ownby, Jonathan G., Stephens, Nashia, Gyurko, Rita, Rao, Pratibha, Paulus, Kelly, Kipnes, Mark, Ryan, Terri, Iannuzzi, Lisa, Centeno, Gloria, Castro-Revoredo, Iris, Eskeland, Andrew, Swerdloff, Ronald S., Ruiz, Elizabeth, Park, Jean, Hurtado, Maria, Ghazi, Adline , Hamm, M., Ducote, Rosina, Blonde, Lawrence , Williams, Shannon, Wyne, Kathleen , Aldrich, Lindsey, Ahmann, Andrew , Branigan, Deborah , Nakhle, Samer, Sandry, Sasha, Rosal, Rosario, Hardy, Cashmere, Sloan, Lance , Sloan, Kátia Portero , Lerman, Sam, Simmons, Mary, Varela, Tamara Blanco, Gassaway, Franziska, Puckett, Curtiss, Atkinson, Karen, Zimmerman, Michael, Jacobsen, Colleen, Wenker, Matthew, Schultz, Austin, Lender, Dan, Camacho, Allison, Leibowitz, Mark D., Sánchez, Rosario, Delgado, John , Jaasko, Kari, Hsia, Stanley H. , Rodríguez, Cecilia, Guzman, David , Garibay, Lourdes, Chang, Margaret, Nixon, Tatyana, Buse, John B , Christofides, Elena A , Eilerman, Bradley , Handelsman, Yehuda , Kahn, Steven , Rosenstock, Julio , Umpierrez, Guillermo E. , Schlafly, Tina K , Philis-Tsimikas, Athena , DeFronzo, Ralph A , Fonseca, Vivian , Bailey, Timothy S. , Bancos, Irina , Kahn, Steven E. , Pratley, Richard E. , Shambharkar, Samir, Investigators*, CATALYST, Ownby, Jonathan G., Centeno, Gloria, Castro-Revoredo, Iris, Ruiz, Elizabeth, Aldrich, Lindsey, Botte, Jennifer, Hardy, Cashmere, Martin, Maria Jesus , Lovre, Dragana , Simmons, Mary, Pop‐Busui, Rodica , Zimmerman, Michael, Wenker, Matthew, Schultz, Austin, Chang, Margaret, Nixon, Tatyana

Mayo Clinic

Diabetes Care | June 23, 2025 | Volume: 48 | Issue: 12 | Pages: 2036-2044

10.2337/dc25-1055 | PMID 40550011 Get It

OBJECTIVE In many individuals, type 2 diabetes (T2D) remains poorly controlled despite taking multiple glucose-lowering therapies. Several studies have demonstrated that endogenous hypercortisolism is prevalent among these individuals. We tested whether cortisol-directed therapy improves their glycemic control. RESEARCH DESIGN AND METHODS In this prospective, multicenter, double-blind study, 136 individuals with T2D (hemoglobin A1c [HbA1c] 7.5%–11.5% [58–102 mmol/mol] on multiple medications) and hypercortisolism (by dexamethasone suppression test) were randomized 2:1 to the glucocorticoid receptor antagonist mifepristone (300–900 mg once daily; n = 91) or placebo (n = 45) for 24 weeks, with stratification by presence/absence of an adrenal imaging abnormality. The primary end point was the change in HbA1c. Secondary end points included changes in glucose-lowering medications, weight, and waist circumference and safety. RESULTS Mean baseline HbA1c in the study cohort was 8.55% (69.9 mmol/mol). At 24 weeks, the least squares mean (LSM) difference from placebo in HbA1c was −1.32% (95% CI −1.81 to −0.83; P &lt; 0.001). Participants receiving mifepristone experienced reductions in body weight and waist circumference (placebo-adjusted LSM differences of −5.12 kg [95% CI −8.20 to −2.03] and −5.1 cm [−8.23 to −1.99], respectively). Of participants on mifepristone, 46% discontinued therapy, compared with 18% on placebo. Adverse events with mifepristone (&gt;10% of participants) included hypokalemia, fatigue, nausea, vomiting, headache, peripheral edema, diarrhea, and dizziness, consistent with mifepristone’s known tolerability profile. Increases in blood pressure also occurred. CONCLUSIONS In individuals with inadequately controlled T2D and hypercortisolism, cortisol-directed medical therapy with mifepristone reduced HbA1c, with a manageable tolerability profile.
O21 Long-term efficacy and safety of filgotinib 200 mg in ulcerative colitis: 5-year interim data from SELECTIONLTE
Arnott, Ian , Feagan, Brian G. , Schreiber, S, Kim, Hyo Jong , Faes, Margaux , Mangili, Alexandra, Peyrin-Biroulet, Laurent, Matsuoka, Katsuyoshi , Rogler, Gerhard , Laharie, David , Vermeire, Séverine , Danese, Silvio , Loftus, Edward V. , Beales, Ian , Schreiber, Stefan , Rudolph, Christine , Peyrin‐Biroulet, Laurent

Mayo Clinic

Oral Presentations | June 23, 2025 | Volume: No volume available | Issue: No issue available | Pages: A15-A15

10.1136/gutjnl-2025-bsg.21 Get It

Recent-onset atrial fibrillation: challenges and opportunities
Svennberg, Emma , Andrade, Jason G. , Anselmino, Matteo , Biton, Yitschak , Brandes, Axel , Buckley, Claire , Espuny, Josep Lluis Clua , Doehner, Wolfram , Domínguez, Helena , Fauchier, Laurent , Glotzer, Taya V. , Hendriks, Jeroen , Hills, Mellanie True , Hindricks, Gerhard , Joung, Boyoung , Levin, Lars‐Åke , Liu, Shaowen , Lobban, Trudie , Macfarlane, Peter W. , Mairesse, Georges H. , Marcus, Gregory M. , Orchard, J. , Reiffel, James A. , Siontis, Konstantinos C. , Stavrakis, Stavros , Svendsen, Jesper Hastrup , Teh, A. , Tieleman, Robert G , Camm, A. John , Freedman, Ben , Andrade, Jason G , Anselmino, Matteo , Biton, Yitschak , Boriani, Giuseppe , Brandes, Axel , Buckley, Claire , Cameron, Alan C , Lluis Clua Espuny, Josep , Crijns, Harry J G M , Diederichsen, Søren Z , Doehner, Wolfram , Dominguez, Helena , Duncker, David , Fauchier, Laurent , Glotzer, Taya , Guo, Yutao , Haeusler, Karl G , Haim, Moti , Healey, Jeffrey S , Hendriks, Jeroen M , True Hills, Mellanie , Hindricks, Gerhard , Hobbs, F D Richard , Johnson, Linda S B , Joung, Boyoung , Kamel, Hooman , Kirchhof, Paulus , Lane, Deirdre A , Levin, Lars-Åke , Lip, Gregory Y H , Liu, Shaowen , Lobban, Trudie , Macfarlane, Peter W , Mairesse, Georges , Marcus, Gregory M , Noseworthy, Peter A , Ntaios, George , Orchard, Jessica J , Passman, Rod , Reidpath, Daniel D , Reiffel, James A , Ribeiro, Antonio Luiz , Rivard, Lena , Sanders, Prashanthan , Sandhu, Roopinder K , Schnabel, Renate B , Siontis, Konstantinos C , Sposato, Luciano A , Stavrakis, Stavros , Steinhubl, Steven , Svendsen, Jesper Hastrup , Teh, Andrew W , Themistoclakis, Sakis , Tieleman, Robert G , Camm, Alan John , Freedman, Ben , Boriani, Giuseppe , Cameron, Alan C. , Crijns, Harry J.G.M. , Diederichsen, Søren Zöga , Duncker, David , Haim, Moti , Healey, Jeff S. , Hobbs, Richard , Johnson, Linda S.B. , Kamel, Hooman , Kirchhof, Paulus , Lane, Deirdre A. , Noseworthy, Peter A. , Passman, Rod , Rivard, Léna , Sanders, Prashanthan , Schnabel, Renate B. , Sposato, Luciano A. , Tieleman, RG

Mayo Clinic

European Heart Journal | June 23, 2025 | Volume: 47 | Issue: 2 | Pages: 170-187

10.1093/eurheartj/ehaf478 | PMID 40873195 Get It

Abstract Atrial fibrillation (AF) is increasingly diagnosed early, close to its first occurrence due to: (i) increased public awareness with self-screening; (ii) health care initiatives including population screening and opportunistic case finding; and (iii) increased use and surveillance of implantable cardiac devices. At its onset, AF is often low burden, and cardiovascular co-morbidities may be absent or at an early stage. Thus, the management of recent-onset AF has become an issue of growing importance. Professional guidelines have traditionally focused on anticoagulant thromboprophylaxis, generally recommending a cautious approach to rhythm control, and priority has been given to rate control to alleviate symptoms. In recent guidelines, the importance of managing lifestyle and co-morbidities has increased. The AF-SCREEN collaboration proposes that a vigorous approach to active management of recent-onset AF may be warranted. This includes addressing co-morbidities and promoting healthy lifestyles to prevent the emergence or progression of AF and associated cardiovascular disease, as well as the initiation of active rhythm control ± anticoagulation to prevent AF-related morbidity and mortality, including stroke and heart failure (HF). Intuitively, intervention early after AF onset would be beneficial since lifestyle and co-morbidity management, plus rhythm control and anticoagulation, are important contributors to improved outcomes in patients with established AF, but robust evidence is lacking for recent-onset AF. There is a delicate balance between achieving favourable outcomes such as preventing strokes, HF and AF progression vs the complications and potential adverse effects of interventions. Given the serious long-term consequences, innovative approaches are necessary to determine the value and risks of initiating active therapy very early in the course of AF. More data are needed to guide the best management of recent-onset AF, bearing AF burden in mind. Long-term studies using large national databases linked to electronic medical records and rhythm monitoring devices offer excellent opportunities. Shorter-term studies focusing on reducing AF burden to slow AF progression and studies focusing on outcomes such as HF could be used in both randomized clinical trials and observational cohort studies.
Substantia Nigra Iron Deposition in Lewy Body Disease: A Magnetic Resonance Imaging and Neuropathology Study
Diaz‐Galvan, Patricia , Przybelski, Scott A. , Lesnick, Timothy G. , Nguyen, Aivi T. , Reichard, Ross R., Ono, Daisuke , Schwarz, Christopher G., Gunter, Jeffrey L. , Lowe, Val J. , Forsberg, Leah K. , Fields, Julie A. , Savica, Rodolfo , Graff‐Radford, Jonathan , Jones, David, Day, Gregory S. , Graff‐Radford, Neill, Kremers, Walter K. , Petersen, Ronald C., Jack, Clifford R. , Ferman, Tanis J. , Boeve, Bradley F., Kantarci, Kejal , Gunter, Jeffrey, Savica, Rodolfo , Graff-Radford, Jonathan , St Louis, E K , Kantarci, Kejal , Jack, Clifford R , Day, Gregory S , Ferman, Tanis J , Nguyen, Aivi T , Diaz-Galvan, Patricia , Kremers, Walter K , Murray, Melissa E. , Dickson, Dennis W. , Senjem, Matthew L. , Schwarz, Christopher G. , Ramanan, Vijay K. , Jones, David, Botha, Hugo , Louis, Erik K. St. , Knopman, David S. , Graff‐Radford, Neill, Petersen, Ronald C. , Boeve, Bradley F.

Mayo Clinic

Movement Disorders | June 23, 2025 | Volume: 40 | Issue: 10 | Pages: 2129-2138

10.1002/mds.30265 | PMID 40545947 Get It

Abstract Objective To compare iron deposition in the substantia nigra (SN) as measured with quantitative susceptibility mapping (QSM) on antemortem magnetic resonance imaging (MRI) between individuals with and without Lewy‐related pathology at autopsy. Methods We performed a retrospective cohort study including 54 participants who underwent autopsy and antemortem MRI with QSM. Cases were classified as Lewy body disease (LBD)‐present (n = 13) if they had Lewy‐related pathology and LBD‐absent (n = 41) if they did not have Lewy‐related pathology. QSM was calculated for the whole SN and the two subregions: pars compacta (SNc) and pars reticulata (SNr). Nonparametric Wilcoxon rank‐sum tests were used to compare SN QSM values between LBD‐present and LBD‐absent cases. Area under the receiver operating characteristic (ROC) curve (AUC) analyses tested the accuracy of SN QSM values to distinguish the two groups. Associations of QSM values in the SN and its subregions with clinical features were tested with Spearman's correlations. Results The LBD‐present group had higher QSM values in the SNc ( P = 0.008) than the LBD‐absent group with no differences in SNr. QSM values of the SNc distinguished LBD‐present and LBD‐absent cases with good accuracy (AUC = 0.74) and correlated with the presence of parkinsonism and parkinsonism severity. Conclusions This study provides neuropathological confirmation of the utility of SNc QSM as an in vivo biomarker of Lewy‐related pathology. Imaging evidence of abnormal iron deposition in the SNc could potentially serve as a biomarker for inclusion in emerging research frameworks aimed at defining individuals with LBD based on their biological characteristics. Ultimately, this could facilitate more precise diagnoses and guide treatment strategies in LBD. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Gastric Accommodation and Impact on Emptying of Solids in Gastroparesis
Yang, David Yi , Abdelnaem, Nada, Matar, Ayah , Camilleri, Michael , Matar, Ayah , Matar, Ayah

Mayo Clinic

Neurogastroenterology & Motility | June 23, 2025 | Volume: 37 | Issue: 12 | Pages: No page available

10.1111/nmo.70111 | PMID 40545643 Get It

ABSTRACT Background In healthy controls, higher gastric accommodation (GA) was associated with slower gastric emptying (GE) of solids. Aims In patients with gastroparesis: (1) To investigate the association between GA and GE of solids. (2) To assess the prevalence of abnormally high GA. Methods An electronic medical records (EMR) review (2010–2024) was conducted on 745 adult patients with measured GA following 300 kcal Ensure using SPECT, and scintigraphy‐based GE of solids (320 kcal, 30% fat, egg meal). Among these patients, 284 had gastroparesis (GE < 25% emptied at 2 h or < 75% emptied at 4 h). Spearman correlation analysis examined associations between GA volume or ratio and GE at 1, 2, and 4 h, and GE T 1/2 . Results Weak positive correlations were observed between GA volume and GE of solids % at 1 and 2 h (respectively R s = 0.148, p = 0.0234, and R s = 0.121, p = 0.042). In addition, there was a correlation between GA ratio and GE of solids % at 2 h ( R s = 0.143, p = 0.0160). However, there were no significant correlations of GA with GE % at 4 h or GE T 1/2 . Among the 284 patients with gastroparesis, we had documented increased GA, assessed by postprandial minus preprandial gastric volume (> 640 mL), in 7.75%, and increased GA by GA ratio > 3.85 in 22.9%. Conclusions Among patients with gastroparesis, higher GA is associated with accelerated GE of solids in the first 2 h, though the effect size is small. There is no significant effect on delayed GE at 4 h or GE T 1/2 .
Associations of educational level with ECG-derived cardiovascular ageing in a population-based cohort: a mediation analysis from the Tromsø Study
Vijayakumar, A. , Wilsgaard, Tom , Schirmer, Henrik , Lopez‐Jimenez, Francisco, Leon, David A. , Iakunchykova, Olena, Panthalanickal Vijayakumar, Arya , Leon, David , Lindekleiv, Haakon , Attia, Zachi I. , López-Jiménez, Francisco , Iakunchykova, Olena

Mayo Clinic

BMJ Open | June 22, 2025 | Volume: 15 | Issue: 6 | Pages: e088671

10.1136/bmjopen-2024-088671 | PMID 40545308 Get It

Objective To assess the association between educational level and cardiovascular age acceleration metric derived from ECG, and to determine whether this association is mediated by established cardiovascular disease (CVD) risk factors. Design Prospective population-based cohort study (the Tromsø Study). Setting General population of the Tromsø municipality, Norway. Participants The study sample consisted of 4367 participants of the Tromsø Study, who took part in both Tromsø6 (2007–2008) and Tromsø7 (2015–2016), had a 12-lead ECG obtained at Tromsø7 and did not report a history of heart attack, stroke or atrial fibrillation. Primary outcome measures δ-age, a biomarker of cardiovascular ageing, is defined as the difference (in years) between an individual’s ECG-predicted heart age and their chronological age. ECG-predicted heart age was estimated using a previously validated deep neural network. Results Our findings indicate an inverse association between education and δ-age, with a regression coefficient per increment increase in education of −0.24 (95% CI −0.41 to –0.07) in the overall sample, −0.38 (95% CI −0.59 to –0.16) for women and −0.04 (95% CI −0.31 to 0.23) for men. Participants with the highest level of education (university/college for 4 or more years) had the lowest estimated δ-age with a regression coefficient of −0.69 years (95% CI −1.23 to –0.16) compared with the group with primary education for the overall sample, −1.05 years (95% CI −1.73 to –0.37) for women and −0.15 years (95% CI −1.03 to 0.73) for men. CVD risk factors mediated up to 75% of the association between overall education and δ-age, and 80% of the association among those with the highest education level (university/college for 4 or more years). Among women, 50% of the effect of overall education on δ-age was mediated by CVD risk factors, rising to 53% in the category with the highest level of education. However, in the subsample of men, there was no significant association between education and δ-age, and the mediation analysis produced natural direct and indirect effects pointing in opposite directions. Conclusions Cardiovascular ageing is inversely associated with educational level, an effect that appears to be largely mediated through established risk factors.
Primary Extranodal Follicular Lymphoma: A Retrospective Survey of the International Extranodal Lymphoma Study Group (IELSG)
Conconi, Annarita , Vannata, Barbara , Ramírez‐Ibarguen, Ana Florencia, Lobetti‐Bodoni, Chiara, Pirosa, Maria Cristina , Mian, Michael , Ferreri, Andrés J.M. , Ryan, G.B., Pangalis, Gerassimos A. , Cabrera, María Elena , Aurer, Igor , Visco, Carlo , Casaluci, Gloria Margiotta , Hricko, Samuel, Stathis, Anastasios , Mazzucchelli, Luca, Ponzoni, Maurilio, Federico, Massimo, Gaïdano, Gianluca , López‐Guillermo, Armando , Pro, Barbara, Rossi, Davide, Nowakowsky, Grzegorz, Janikova, Andrea , Vannata, Barbara , Pirosa, Maria Cristina , Cabrera, Maria Elena , Luminari, Stefano , Zucca, Emanuele , Gaidano, Gianluca , Belada, David , Luminari, Stefano , Montoto, Silvia , Tsang, Richard , Procházka, Vít , Ponzoni, Maurilio, Rossi, Davide, Cascione, Luciano , Trněný, Marek , Zucca, Emanuele

Mayo Clinic

Hematological Oncology | June 22, 2025 | Volume: 43 | Issue: 4 | Pages: No page available

10.1002/hon.70111 | PMID 40544479 Get It

ABSTRACT The characteristics at diagnosis and clinical course of primary extranodal follicular lymphoma (EFL) have not been extensively described. The International Extranodal Lymphoma Study Group (IELSG) conducted an international retrospective survey aimed to describe the clinical features at diagnosis and the outcomes of FL cases with a clinically dominant extranodal component. The dataset included 605 pathologically reviewed cases from 19 different countries, and their outcomes were compared to those of nodal follicular lymphomas. The two most common presentation sites for EFL were the skin ( n = 334) and the gastrointestinal tract ( n = 72), with 22 cases having primary duodenal localization. These subsets exhibited unique features at diagnosis and significantly different overall survival (OS) patterns. After a median follow‐up of 5.5 years, primary cutaneous lymphomas showed a superior outcome [10‐year OS: 89% (95% CI, 83%–93%)], while primary gastrointestinal lymphomas had an intermediate outcome [10‐year OS: 79% (95% CI, 59%–90%)]. Among the gastrointestinal lymphomas, primary duodenal lymphomas tended toward the best outcome [10‐year OS: 95% (95% CI, 69%–99%)]. Other primary extranodal sites had inferior outcomes [10‐year OS: 59% (95% CI, 48%–68%)], similar to primary nodal lymphomas [10‐year OS: 57% (95% CI, 49%–64%)]. These findings support the identification of specific primary FL localizations as distinct entities with particular clinical and biological characteristics.
International Consensus Histopathological Criteria for Subtyping Idiopathic Multicentric Castleman Disease Based on Machine Learning Analysis
Nishimura, Midori Filiz , Haratake, Tomoka , Nishimura, Yoshito , Nishikori, Asami , Sumiyoshi, Remi , Ujiie, Hideki , Kawahara, Yuri, Ueki, Masao , Laczkó, Dorottya , Oksenhendler, Éric , Kawakami, Atsushi , Koga, Tomohiro , Oksenhendler, Eric , Fajgenbaum, David C , van Rhee, Frits , Sato, Yasuharu , Nishimura, Yoshito , Kawahara, Yuri, Fajgenbaum, David C. , Rhee, Frits van

Mayo Clinic

American Journal of Hematology | June 20, 2025 | Volume: 100 | Issue: 9 | Pages: 1502-1512

10.1002/ajh.27743 | PMID 40540535 Get It

ABSTRACTIdiopathic multicentric Castleman disease (iMCD) is a rare lymphoproliferative disorder classified into three recognized clinical subtypes—idiopathic plasmacytic lymphadenopathy (IPL), TAFRO, and NOS. Although clinical criteria are available for subtyping, diagnostically challenging cases with overlapping histopathological features highlight the need for an improved classification system integrating clinical and histopathological findings. We aimed to develop an objective histopathological subtyping system for iMCD that closely correlates with the clinical subtypes. Excisional lymph node specimens from 94 Japanese iMCD patients (54 IPL, 28 TAFRO, 12 NOS) were analyzed for five key histopathological parameters: germinal center (GC) status, plasmacytosis, vascularity, hemosiderin deposition, and “whirlpool” vessel formation in GC. Using hierarchical clustering, we visualized subgroups and developed a machine learning‐based decision tree to differentiate the clinical subtypes and validated it in an external cohort of 12 patients with iMCD. Hierarchical cluster analysis separated the IPL and TAFRO cases into mutually exclusive clusters, whereas the NOS cases were interspersed between them. Decision tree modeling identified plasmacytosis, vascularity, and whirlpool vessel formation as key features distinguishing IPL from TAFRO, achieving 91% and 92% accuracy in the training and test sets, respectively. External validation correctly classified all IPL and TAFRO cases, confirming the reproducibility of the system. Our histopathological classification system closely aligns with the clinical subtypes, offering a more precise approach to iMCD subtyping. It may enhance diagnostic accuracy, guide clinical decision‐making for predicting treatment response in challenging cases, and improve patient selection for future research. Further validation of its versatility and clinical utility is required.
Surgical Treatment and Complications of Lateral Extra‐articular Procedures in the Anterior Cruciate Ligament–Reconstructed Knee: Part II of an International Consensus Statement
Sonnery‐Cottet, Bertrand , Carrozzo, Alessandro , Saithna, Adnan , Vieira, Thaïs Dutra , Musahl, Volker , Helito, Camilo Partezani , Panel, The International Experts, Bedi, Asheesh, Bryant, Dianne, Cavaignac, Etienne, Chahla, Jorge, Claes, Steven, Cordasco, Frank, Daggett, Matt, Devitt, Brian, Feller, Julian, Fink, Christian, Frank, Rachel, Geeslin, Andrew, Grassi, Alberto, Green, Daniel, Guenther, Daniel, Heard, Mark, Herbst, Elmar, Hopper, Graeme, Inderhaug, Eivind, Irrgang, James, Kaeding, Christopher, Kittl, Christopher, Kocher, Mininder, Koga, Hideyuki, Krych, Aaron J., LaPrade, Robert, Levy, Bruce, Litchfield, Robert Bruce, Lording, Tim, Lowe, Walter, MacDonald, Peter, Marx, Robert, Moatshe, Gilbert, Neri, Thomas, Ouanezar, Herve, Padua, Vitor Barion de Castro, Parker, David, Pioger, Charles, Servien, Elvire, Sherman, Seth, Smith, Patrick, Spalding, Tim, Tapasvi, Sachin, Verdonk, Peter, Williams, Andy, Xerogeanes, John, Young, Simon W., Monaco, Edoardo , Getgood, Alan , Panel, The International Experts, Bedi, Asheesh, Bryant, Dianne, Cavaignac, Etienne, Chahla, Jorge, Claes, Steven, Cordasco, Frank, Daggett, Matt, Devitt, Brian, Feller, Julian, Fink, Christian, Frank, Rachel, Geeslin, Andrew, Grassi, Alberto, Green, Daniel, Guenther, Daniel, Heard, Mark, Herbst, Elmar, Hopper, Graeme, Inderhaug, Eivind, Irrgang, James, Kaeding, Christopher, Kittl, Christopher, Kocher, Mininder, Koga, Hideyuki, Krych, Aaron J., LaPrade, Robert, Levy, Bruce, Litchfield, Robert Bruce, Lording, Tim, Lowe, Walter, MacDonald, Peter, Marx, Robert, Moatshe, Gilbert, Neri, Thomas, Ouanezar, Herve, Padua, Vitor Barion de Castro, Parker, David, Pioger, Charles , Servien, Elvire, Sherman, Seth, Smith, Patrick, Spalding, Tim, Tapasvi, Sachin, Verdonk, Peter, Williams, Andy, Xerogeanes, John, Young, Simon W.

Mayo Clinic

Arthroscopy | June 20, 2025 | Volume: 41 | Issue: 9 | Pages: 3313-3321

10.1016/j.arthro.2025.06.013 | PMID 40544924 Get It

Purpose To establish international expert consensus on surgical techniques, complications, and rehabilitation protocols for lateral extra‐articular procedures (LEAPs) performed adjunctively with anterior cruciate ligament reconstruction. Methods Fifty‐five knee surgeons from 17 countries on 5 continents completed a 3‐round modified Delphi process. In the final round, 16 statements on LEAP techniques and complications were scored on a 5‐point Likert scale; ≥75% “agree/strongly agree” constituted consensus. When appropriate, strength of recommendation was graded. Statements lacking support were revised until consensus or abandonment. Results Six statements achieved unanimous consensus (100%), 2 had strong consensus (90%‐99.9%), and 3 reached consensus (75%‐89.9%); 4 were removed. Key technical recommendations were as follows: (1) in iliotibial band procedures, the graft strip should pass beneath the lateral collateral ligament; (2) an anatomic technique is mandatory for anterolateral ligament reconstruction; and (3) no single LEAP is clinically superior to another. Unanimous agreement indicated that modern LEAPs do not increase lateral compartment osteoarthritis risk, carry a low complication rate, and do not necessitate changes to rehabilitation or return‐to‐play timelines. Conclusions Consensus defined core surgical principles and confirmed the safety of adding LEAPs to anterior cruciate ligament reconstruction. When an iliotibial band graft is used, it should be routed deep to the lateral collateral ligament and fixed between 0° and 60° of knee flexion under low tension. For anterolateral ligament reconstruction, femoral fixation should be in full extension at a posterior‐proximal point relative to the lateral epicondyle. Although no single LEAP proved superiority, adherence to these principles permits safe, effective surgery without altering standard rehabilitation or return‐to‐sport protocols and without increasing osteoarthritis risk. Level of Evidence Level V, expert opinion.